



New Drug Delivery across the Blood–Brain Barrier

Guest Editor:

Prof. Dr. Xavier Declèves

Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l'Observatoire, 75006 Paris, France

Deadline for manuscript submissions:

closed (31 August 2020)

Message from the Guest Editor

Dear Colleagues,

Drug delivery into the central nervous system (CNS) is modulated by blood–brain interfaces. The blood–brain barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid barrier (BAB) are key interfaces regulating the exchange of substances between the blood, the CSF, and the brain parenchyma. Drug delivery to the CNS can thus be limited due to unfavorable physicochemical properties, efficient active brain to blood carrier-mediated efflux, and/or poor active blood to brain carrier-mediated influx. Several strategies are currently developed to increase CNS drug delivery of small and large molecular weight drugs, including direct administration into the brain parenchyma, methods disrupting BBB integrity, development of specific chemicals or antisense oligonucleotides inhibiting efflux transporter activity, rational drug design decreasing substrate recognition by efflux transporters and/or increasing transport by influx transporters or carrier-mediated transcytosis receptors, and development of nanomedicines and biologics from microbiological origin targeting the BBB and delivering drugs into the brain parenchyma.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma